Our Focus

Working to reshape the treatment path for progressive cancers

At PharmaEssentia, we are focused on providing new therapeutic solutions for patients with myeloproliferative neoplasms (MPNs) and other hematological diseases. Our motivation is the unmet need for more tolerable, effective, long-term treatments to preserve patients’ health and well-being.

Developing new early treatment options

Patients with myeloproliferative neoplasms (MPNs) have limited treatment options today. A group of rare, chronic blood cancers, MPNs gradually impact patients’ quality of life and can lead to life-threatening forms of cancer. Existing treatments for some MPNs, such as polycythemia vera (PV) and essential thrombocythemia (ET), are focused on managing the symptoms and reducing the risk of complications. PharmaEssentia is working diligently to provide physicians and patients with options that aim to reduce the risk of disease progression.

Rethinking existing therapies

At PharmaEssentia, we’re rethinking the potential of  interferonsor treating MPNs and other hematological diseases. Trusted and proven as a treatment for other conditions, interferons have not been commonly applied to MPNs. We’re working to change this, applying novel science to the challenge. Our goal: to give physicians a new option for early intervention designed to extend the preservation of health and quality of life.

Take a closer look at our science →

Focusing on rare, chronic blood cancers

Our initial focus in the U.S. is in polycythemia vera (PV), a challenging disease marked by an over-production of red blood cells, and soon moving to essential thrombocythemia (ET), an over-production of platelets. These conditions are part of a group of MPNs and can progress to more deadly cancers over time.1

View our development pipeline →

160,000 people in the U.S. are living with PV1

An estimated 1 to 24 per 1 million people worldwide have ET2

Only 42% of high-risk PV patients receive cytoreductive treatment3

  1. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600
  2. https://ghr.nlm.nih.gov/condition/essential-thrombocythemia#statistics
  3. Truven Health Marketscan; Paranagama D et al, Exp Hematol Oncol. 2018 Jul 9;7:16